Ono Pharmaceutical Co Ltd banner

Ono Pharmaceutical Co Ltd
F:ON4

Watchlist Manager
Ono Pharmaceutical Co Ltd Logo
Ono Pharmaceutical Co Ltd
F:ON4
Watchlist
Price: 11.905 EUR -0.92% Market Closed
Market Cap: €5.6B

Wall St Price Targets

ON4 Price Targets Summary
Ono Pharmaceutical Co Ltd

Wall Street analysts forecast ON4 stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ON4 is 10.833 EUR with a low forecast of 8.334 EUR and a high forecast of 14.2 EUR.

Lowest Forecast
Price Target
8.334 EUR
30% Downside
Average Forecast
Price Target
10.833 EUR
9% Downside
Highest Forecast
Price Target
14.2 EUR
19% Upside
Ono Pharmaceutical Co Ltd Competitors:
Price Targets

Revenue
Forecast

9% / Year
Past Growth
-6% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
9% / Year
Past Growth
-6% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 2 years is -6%.

Gross Profit
Forecast

9% / Year
Past Growth
-4% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
9% / Year
Past Growth
-4% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 14 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 2 years is -4%.

Operating Income
Forecast

7% / Year
Past Growth
30% / Year
Estimated Growth
Estimates Accuracy
-17%
Average Miss
7% / Year
Past Growth
30% / Year
Estimated Growth
Estimates Accuracy
-17%
Average Miss

Over the last 14 years, the compound annual growth rate for Operating Income has been 7%. The projected CAGR for the next 1 year is 30%.

Pre-Tax Income
Forecast

6% / Year
Past Growth
-6% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
6% / Year
Past Growth
-6% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 6%. The projected CAGR for the next 2 years is -6%.

Net Income
Forecast

8% / Year
Past Growth
-6% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
8% / Year
Past Growth
-6% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 14 years, the compound annual growth rate for Net Income has been 8%. The projected CAGR for the next 2 years is -6%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is ON4's stock price target?
Price Target
10.833 EUR

According to Wall Street analysts, the average 1-year price target for ON4 is 10.833 EUR with a low forecast of 8.334 EUR and a high forecast of 14.2 EUR.

What is the Revenue forecast for Ono Pharmaceutical Co Ltd?
Projected CAGR
-6%

Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 2 years is -6%.

What is the Gross Profit forecast for Ono Pharmaceutical Co Ltd?
Projected CAGR
-4%

Over the last 14 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 2 years is -4%.

What is the Operating Income forecast for Ono Pharmaceutical Co Ltd?
Projected CAGR
30%

Over the last 14 years, the compound annual growth rate for Operating Income has been 7%. The projected CAGR for the next 1 year is 30%.

What is the Pre-Tax Income forecast for Ono Pharmaceutical Co Ltd?
Projected CAGR
-6%

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 6%. The projected CAGR for the next 2 years is -6%.

What is the Net Income forecast for Ono Pharmaceutical Co Ltd?
Projected CAGR
-6%

Over the last 14 years, the compound annual growth rate for Net Income has been 8%. The projected CAGR for the next 2 years is -6%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett